when to stop eliquis in elderly

Project Fab

4 min read

·

20-03-2025

1

0

Share

When to Stop Eliquis in Elderly Patients: A Complex Decision

Eliquis (apixaban) is a widely prescribed anticoagulant used to prevent stroke and blood clots in patients with atrial fibrillation (AFib) and other conditions. While highly effective, the decision to discontinue Eliquis, particularly in elderly patients, requires careful consideration of numerous factors. Stopping Eliquis prematurely can increase the risk of thromboembolic events (blood clots), while prolonged use carries its own set of risks, including bleeding complications. This article explores the complexities of deciding when to stop Eliquis in elderly individuals, emphasizing the crucial role of individualized assessment and shared decision-making.

Understanding the Risks and Benefits of Eliquis in the Elderly

The elderly population is particularly susceptible to both thromboembolic events and bleeding complications. Age itself is a significant risk factor for both. Older adults often have age-related changes in their kidneys and liver, impacting drug metabolism and clearance. This can lead to an increased risk of adverse effects, including bleeding, with Eliquis. Furthermore, the elderly frequently have comorbidities (other medical conditions) that can further complicate the decision of whether to continue or discontinue Eliquis. These comorbidities might include:

• Frailty: Frailty increases the risk of falls and injuries, making bleeding events more likely and potentially more severe.
• Cognitive impairment: Difficulty understanding the risks and benefits of medication can hinder informed decision-making.
• Renal impairment: Reduced kidney function can affect Eliquis clearance, potentially leading to elevated drug levels and increased risk of bleeding.
• Gastrointestinal issues: Increased risk of gastrointestinal bleeding.
• Polypharmacy: Taking multiple medications increases the risk of drug interactions and bleeding complications.
• Prior bleeding history: A history of bleeding significantly increases the risk of future bleeding events.

Despite these risks, the benefits of Eliquis in preventing stroke and blood clots in elderly patients with AFib remain significant. Stroke is a devastating event with potentially fatal consequences, particularly in older adults. Therefore, the decision to discontinue Eliquis should always weigh the risk of a thromboembolic event against the risk of bleeding.

Situations Where Stopping Eliquis Might Be Considered

Several clinical situations might prompt a discussion about stopping Eliquis in elderly patients:

• Major surgery or invasive procedure: Eliquis needs to be stopped before most surgeries and invasive procedures to minimize the risk of bleeding. The timing of discontinuation depends on the specific procedure and the patient's overall health. Bridging therapy with other anticoagulants might be necessary.
• Significant bleeding event: A major bleeding event is a strong indication to stop Eliquis. The physician will need to assess the cause of the bleeding and evaluate the overall risk-benefit profile before considering restarting anticoagulation.
• Development of new comorbidities: The emergence of new conditions, such as severe kidney disease or a significant increase in the risk of falls, might necessitate a re-evaluation of Eliquis's continued use.
• Patient preference: While medical factors play a crucial role, patient preferences should always be respected. A shared decision-making approach, involving open communication between the patient, their family, and their healthcare provider, is crucial.
• Unmanageable side effects: If the patient experiences intolerable side effects, such as persistent nausea, vomiting, or gastrointestinal discomfort, adjusting the dose or switching to a different anticoagulant might be considered. Stopping the medication completely should be considered only if other options are not feasible or effective.
• End-of-life care: In end-of-life situations, the benefits of anticoagulation might be outweighed by the risks of bleeding complications. A careful assessment of the patient's prognosis and quality of life is essential.

The Importance of Individualized Assessment and Shared Decision-Making

The decision to stop Eliquis should never be taken lightly and should always be based on an individualized risk-benefit assessment. This assessment should involve:

• Comprehensive medical history: A detailed review of the patient's medical history, including comorbidities, medication list, and prior bleeding episodes.
• Physical examination: A thorough physical examination to assess the patient's overall health and functional status.
• Laboratory tests: Blood tests to evaluate kidney function, liver function, and coagulation parameters.
• Risk stratification: Utilizing validated risk scores, such as the CHA2DS2-VASc score for stroke risk assessment in AFib patients, to quantify the risk of thromboembolic events.
• Patient-centered communication: Open and honest communication with the patient and their family to understand their concerns, preferences, and goals of care.

This shared decision-making process ensures that the treatment plan aligns with the patient's values and preferences, fostering trust and adherence to the chosen course of action.

Transitioning Off Eliquis: A Gradual Approach

Abruptly stopping Eliquis can significantly increase the risk of blood clots. Therefore, if the decision is made to discontinue the medication, it should be done gradually under close medical supervision. The physician will determine the appropriate tapering schedule based on individual factors. Regular monitoring for bleeding and thromboembolic events during and after the tapering period is essential.

Conclusion

The decision of when to stop Eliquis in elderly patients is a complex one requiring careful consideration of multiple factors. A shared decision-making approach, incorporating a comprehensive assessment of risks and benefits, is crucial to ensure patient safety and adherence to the treatment plan. Close collaboration between the patient, their family, and their healthcare providers is vital to make an informed and appropriate decision that prioritizes the patient's well-being. This process should always involve weighing the risks of thromboembolic events against the risks of bleeding, considering comorbidities, and respecting the patient's wishes and preferences. Regular monitoring is crucial throughout the process, ensuring timely intervention if complications arise.